Literature DB >> 3981950

[Use of low molecular-weight heparin in hemodialysis patients].

J Schrader, J Rieger, H Müschen, W Stibbe, H Köstering, P Kramer, F Scheler.   

Abstract

Low-molecular-weight (LMW) heparin has been compared to standard unfractionated (UF) heparin in a total of 49 patients on hemodialysis and hemofiltration in order to determine the necessary therapeutic dose and its effect on the coagulation system. A LMW heparin dose corresponding to 50% of the normal UF heparin dose was found to produce similar plasma heparin levels (anti-FXa-U/ml) in particular on minimal heparinization. At higher doses, UF heparin produced a more marked increase in plasma-heparin than did LMW heparin. Highly significant differences were found between UF and LMW heparin in their effects on PTT and thrombin time. Partial thromboplastin time (PTT) increased under UF heparin by an average of 120 s whereas LMW heparin only produced an increase of 5-7 s. Thrombin time was increased by 250-280 s under UF heparin and by 5-8 s under LMW heparin. With this LMW heparin dose of 50% of the UF heparin dose, no thrombosis of the extracorporal system occurred and no macroscopic detectable thrombotic material was found in the dialyzers or filters. No significant differences were observed between the effects of UF and LMW heparin on Factor VIII activity and fibrin monomers, so that a difference in coagulation activation between the two heparins can be excluded. Furthermore, there were no changes in thromboplastin time according to Quick, fibrinogen, antithrombin III, plasminogen, and a2-antiplasmin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3981950     DOI: 10.1007/bf01733067

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  19 in total

1.  Platelet function in patients on maintenance hemodialysis: depressed or enhanced?

Authors:  G Remuzzi; A Benigni; P Dodesini; A Schieppati; E Gotti; M Livio; G Mecca; B Donati; G de Gaetano
Journal:  Clin Nephrol       Date:  1982-02       Impact factor: 0.975

2.  Anticoagulant properties of heparin and heparin fractions.

Authors:  E Holmer
Journal:  Scand J Haematol Suppl       Date:  1980

3.  Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin.

Authors:  E Holmer; U Lindahl; G Bäckström; L Thunberg; H Sandberg; G Söderström; L O Anderson
Journal:  Thromb Res       Date:  1980-06-15       Impact factor: 3.944

4.  Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractions.

Authors:  M G Huisse; M C Guillin; A Bezeaud; F Toulemonde; M Kitzis; B Andreassian
Journal:  Thromb Res       Date:  1982-08-15       Impact factor: 3.944

5.  [Long-term results of chronic intermittent dialysis treatment].

Authors:  H G Sieberth; J Kindler; M Vlaho; W M Glöckner; J Freiberg; R Pelzer
Journal:  Med Welt       Date:  1982-10-01

Review 6.  Effect of heparin and heparin fractions on platelet aggregation.

Authors:  E W Salzman; R D Rosenberg; M H Smith; J N Lindon; L Favreau
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

7.  [Antithrombin III substitution in dialysis-dependent renal insufficiency].

Authors:  J Schrader; H Köstering; P Kramer; F Scheler
Journal:  Dtsch Med Wochenschr       Date:  1982-12-03       Impact factor: 0.628

8.  Anticoagulant activities of high and low molecular weight heparin fractions.

Authors:  T W Barrowcliffe; E A Johnson; C A Eggleton; G Kemball-Cook; D P Thomas
Journal:  Br J Haematol       Date:  1979-04       Impact factor: 6.998

9.  Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.

Authors:  V V Kakkar; B Djazaeri; J Fok; M Fletcher; M F Scully; J Westwick
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-06

10.  Interaction of lipoprotein lipase with native and modified heparin-like polysaccharides.

Authors:  G Bengtsson; T Olivecrona; M Höök; J Riesenfeld; U Lindahl
Journal:  Biochem J       Date:  1980-09-01       Impact factor: 3.857

View more
  3 in total

1.  [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].

Authors:  J Harenberg; C Giese; A Knödler; R Zimmermann; G Schettler
Journal:  Klin Wochenschr       Date:  1986-11-17

2.  [Ambulatory long-term prevention of thromboembolism with low-molecular weight heparin].

Authors:  J Harenberg; G Leber; J Augustin; R Raedsch; F Schwarz; A Stiehl; R Zimmermann
Journal:  Klin Wochenschr       Date:  1987-04-01

Review 3.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.